A Phase 2a, Open-Label Study to Evaluate the Safety and Efficacy of Selgantolimod (SLGN)-Containing Combination Therapies for the Treatment of Chronic Hepatitis B (CHB)
The primary objectives of this study are to evaluate the safety and tolerability of study treatment(s) (selgantolimod-containing combination therapies) and to evaluate the efficacy of study treatment(s) as measured by the proportion of participants who achieve functional cure, defined as hepatitis B surface antigen (HBsAg) loss and hepatitis B virus (HBV)deoxyribonucleic acid (DNA) < lower limit of quantitation (LLOQ) at Follow-up (FU) Week 24 in participants with chronic hepatitis B (CHB).
View More
Age
18 Years - 65 Years
Sex
All
Healthy Volunteers
No
Medical Condition
Chronic Hepatitis B
Gender
N/A
Date
August 2021 - January 2024
Study Type
Interventional
Study Phase
Phase 2
Product
Tenofovir Alafenamide, VIR-2218, Nivolumab, Selgantolimod
Liverpool, New South Wales, Australia, 2170
Parkville, Victoria, Australia, 3050
Aalborg, Denmark, DK9000
Aarhus N, Denmark, 8200
Hvidovre, Denmark, 2650
Odense, Denmark, DK5000
Hong Kong, Hong Kong
Hong Kong, Hong Kong
Shatin, Hong Kong
Tai Po, Hong Kong
Seoul, Korea, Republic of, 03080
Seoul, Korea, Republic of, 05505
Seoul, Korea, Republic of, 06351
Seoul, Korea, Republic of, 06591
Seoul, Korea, Republic of, 06973
Seoul, Korea, Republic of, 120-752
Seoul, Korea, Republic of, 152-703
Grafton, New Zealand, 1010
Singapore, Singapore, 119228
Singapore, Singapore, 529889
Singapore, Singapore
Bangkok, Thailand, 10330
Bangkok, Thailand, 10400
Bangkok, Thailand, 10700
Muang, Thailand, 50200
London, United Kingdom, SE5 9RS
Share Trial